ArticleEJHaem2026
Infection Incidence and Survival in Patients With Multiple Myeloma and Chronic Lymphocytic Leukaemia: A Growing Concern in the Era of Modern Therapies.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients with multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL) are burdened by immunodeficiency due to treatment and underlying disease. Infection-related mortality remains a significant concern for patients' overall survival (OS). Methods: This Swedish, population-based study examined incidence of infections and OS in patients with MM or CLL between January 2010 and December 2021, using Swedish Cancer Registry data. Results: Overall, 15,766 patients were included (MM: 8532; CLL: 7234); the majority were male (MM: 57%; CLL: 62%); median age was 71 years (range: 19-100 [MM]; 23-102 [CLL]). The proportion with a Charlson Comorbidity Index ≥ 5 was 37% (MM) and 25% (CLL). At least one infection was reported in 66% (MM; Conclusions: This study demonstrates high mortality rates among patients with MM and CLL, due to underlying malignancy and high infection burden. This emphasises the need for optimised anticancer treatments and infection control strategies. Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.